Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma.

Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma.

Show other versions (2)

Bibliographic Details
Main Authors:	Druce, M, Chung, T, Grozinsky-Glasberg, S, Gross, D, Grossman, AB
Format:	Journal article
Language:	English
Published:	2012

Similar Items

Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma
by: Druce, M, et al.
Published: (2012)

Preliminary Report of the Use of Everolimus in a Patient with Progressive Medullary Thyroid Carcinoma
by: Druce, M, et al.
Published: (2010)

The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
by: Grozinsky-Glasberg, S, et al.
Published: (2010)

The Rapamycin Derivative RAD001 (Everolimus) Inhibits Cell Proliferation and Interacts with the Akt-mTOR-p70S6K Pathway in Human Medullary Thyroid Carcinoma Cells
by: Grozinsky-Glasberg, S, et al.
Published: (2009)

Everolimus therapy for progressive adrenocortical cancer.
by: Fraenkel, M, et al.
Published: (2013)

Everolimus therapy for progressive adrenocortical cancer
by: Fraenkel, M, et al.
Published: (2013)

MEDULLARY THYROID CARCINOMA
by: V. S. Medvedev, et al.
Published: (2015-04-01)

Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001).
by: Druce, MR, et al.
Published: (2009)

Metastatic medullary thyroid carcinoma: A case report
by: Mitra Niafar, et al.
Published: (2011-01-01)

Educational Case: Medullary Thyroid Carcinoma
by: Carl T. McGary MD, PhD
Published: (2018-06-01)

The Global mTOR Inhibitor Torin1 Is More Effective than the mTORC1 Inhibitor, Everolimus, Alone or in Combination with Histone Deacetylase Inhibitors, in Suppressing Neuroendocrine Tumor Cell Proliferation
by: Grozinsky-Glasberg, S, et al.
Published: (2011)

Medullary thyroid cancer: molecular biology and novel molecular therapies.
by: Cakir, M, et al.
Published: (2009)

Update of pathology in medullary thyroid carcinoma
by: LIU Zhiyan, YU Yaling, KAKUDO Kennichi
Published: (2023-11-01)

Papillary variant of medullary carcinoma thyroid
by: Saumya Shukla, et al.
Published: (2014-01-01)

Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?
by: Gupta, P, et al.
Published: (2014)

Diagnosis and treatment of medullary thyroid carcinoma: A case report
by: Xin Nie, et al.
Published: (2023-11-01)

An Unusual Variant of Medullary Carcinoma of Thyroid – A Case Report
by: R. Thamil Selvi, et al.
Published: (2011-07-01)

Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
by: Chan, H, et al.
Published: (2010)

Mixed Medullary – Papillary Carcinoma Thyroid: An Uncommon Variant of Thyroid Carcinoma
by: Manjula Jain, et al.
Published: (2014-07-01)

Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?
by: Sen Gupta, P, et al.
Published: (2014)

The role of somatostatin analogues in the treatment of neuroendocrine tumours.
by: Grozinsky-Glasberg, S, et al.
Published: (2008)

Progress of study on medullary thyroid carcinoma with serum calcitonin-negative and large mass
by: LI Rui, LIU Zhuoran, YAN Jiqi
Published: (2022-06-01)

Calcitonin receptor expression in medullary thyroid carcinoma
by: Virginia Cappagli, et al.
Published: (2017-09-01)

Mixed Medullary and Follicular Thyroid Carcinoma (MMFTC)
by: Hasnaini Hasnaini, et al.
Published: (2020-11-01)

Diagnosis and treatment of medullary thyroid carcinoma-an update
by: CHEN Chengkun, GUO Bomin, DENG Xianzhao, WU Bo, FAN Youben
Published: (2022-06-01)

Thirty synchronous medullary and papillary thyroid carcinomas
by: Daqi Zhang, et al.
Published: (2023-03-01)

Design of new drugs for medullary thyroid carcinoma
by: Yanqing Li, et al.
Published: (2022-12-01)

Integrated proteogenomic characterization of medullary thyroid carcinoma
by: Xiao Shi, et al.
Published: (2022-11-01)

Recent Updates on the Management of Medullary Thyroid Carcinoma
by: Bo Hyun Kim, et al.
Published: (2016-09-01)

Trends in the Diagnosis and Treatment of Patients with Medullary Thyroid Carcinoma in Korea
by: Hwa Young Ahn, et al.
Published: (2020-12-01)

Coexistence of medullary thyroid carcinoma and gastric carcinoma: A case report and literature review
by: Xiao-xiong Gan, et al.
Published: (2024-04-01)

Serum Biochemical Markers for Medullary Thyroid Carcinoma: An Update
by: Liu S, et al.
Published: (2024-04-01)

RET splice site variants in medullary thyroid carcinoma
by: Daryoush Saeed-Vafa, et al.
Published: (2024-03-01)

Genetics of Familial Non-Medullary Thyroid Carcinoma (FNMTC)
by: Chiara Diquigiovanni, et al.
Published: (2021-04-01)

New Opportunities for Preoperative Diagnosis of Medullary Thyroid Carcinoma
by: Sergei A. Lukyanov, et al.
Published: (2023-05-01)

Disseminated medullary thyroid carcinoma. Optimal approach to treatment
by: I. S. Romanov, et al.
Published: (2019-01-01)

Coexistence of Medullary and Papillary Thyroid Carcinomas Detected Incidentally
by: Ensar Aydemir, et al.
Published: (2021-03-01)

Oncologic outcomes of calcitonin-negative medullary thyroid carcinoma
by: Wenliang Yue, et al.
Published: (2022-11-01)

Reprogramming of myeloid cells and their progenitors in patients with non-medullary thyroid carcinoma
by: Katrin Rabold, et al.
Published: (2022-10-01)

Calcitonin testing in patients with thyroid nodules for screening medullary thyroid carcinoma: a “gray zone”
by: N. V. Severskaya, et al.
Published: (2022-08-01)